Company profile
Manzo Pharmaceuticals, Inc.
OTC: MNZO · Healthcare · Drug Manufacturers - Specialty & Generic
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
57CFH 75DQ —GM 9SS 47
v0.1 · 45/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$60.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$50.9k
Employees
12
as of 2026-08-02
Market cap
$116.0k
as of 2026-08-02
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$50.9k-$50.9k2025
Operating income-$52.2k-$52.2k2025
Total assets$192.4k$192.4k2015
Liabilities-$11.1k-$11.1k2015
Equity$181.3k$181.3k2015
Revenue trend
FY2003 – FY2025 · USD
FY03
FY04
FY14
FY15
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Manzo Pharmaceuticals, Inc.’s revenue?
Manzo Pharmaceuticals, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
TripSitter Clinic Ltd.——Indigenous Bloom Hemp Corp.——GB Sciences, Inc.——Immunotech Laboratories, Inc.——Drug Free Solution, Inc.——Link Reservations Inc.——Key facts
CEOKenneth Manzo
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMilford, PA
ExchangeOTC: MNZO
Employees12
IPO date1998-12-31
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.